SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more
SK Bioscience Co Ltd (302440) - Net Assets
Latest net assets as of September 2025: ₩2.07 Trillion KRW
Based on the latest financial reports, SK Bioscience Co Ltd (302440) has net assets worth ₩2.07 Trillion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.92 Trillion) and total liabilities (₩847.96 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩2.07 Trillion |
| % of Total Assets | 70.99% |
| Annual Growth Rate | 45.77% |
| 5-Year Change | 666.69% |
| 10-Year Change | N/A |
| Growth Volatility | 185.41 |
SK Bioscience Co Ltd - Net Assets Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual net assets of SK Bioscience Co Ltd from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.02 Trillion | +18.70% |
| 2023-12-31 | ₩1.70 Trillion | -2.17% |
| 2022-12-31 | ₩1.74 Trillion | +8.77% |
| 2021-12-31 | ₩1.60 Trillion | +507.04% |
| 2020-12-31 | ₩263.79 Billion | +13.34% |
| 2019-12-31 | ₩232.73 Billion | +10.44% |
| 2018-12-31 | ₩210.73 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SK Bioscience Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 94014.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩499.76 Billion | 27.72% |
| Other Components | ₩1.30 Trillion | 72.28% |
| Total Equity | ₩1.80 Trillion | 100.00% |
SK Bioscience Co Ltd Competitors by Market Cap
The table below lists competitors of SK Bioscience Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LX International Corp
KO:001120
|
$773.58 Million |
|
Klabin S.A
SA:KLBN3
|
$773.72 Million |
|
NISSHIN OILLIO GRP
F:8WC
|
$773.73 Million |
|
DTS Corporation
F:DA9
|
$773.82 Million |
|
Cleanaway Co Ltd
TW:8422
|
$773.23 Million |
|
Ennoconn Corp
TW:6414
|
$772.89 Million |
|
Korian S.A.
LSE:0OPS
|
$772.84 Million |
|
Parksystems Corp
KQ:140860
|
$772.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SK Bioscience Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,703,855,316,370 to 1,802,565,226,090, a change of 98,709,909,720 (5.8%).
- Net loss of 53,881,198,900 reduced equity.
- New share issuances of 75,680,234,210 increased equity.
- Other factors increased equity by 76,910,874,410.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-53.88 Billion | -2.99% |
| Share Issuances | ₩75.68 Billion | +4.2% |
| Other Changes | ₩76.91 Billion | +4.27% |
| Total Change | ₩- | 5.79% |
Book Value vs Market Value Analysis
This analysis compares SK Bioscience Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.69x to 1.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩3443.36 | ₩43700.00 | x |
| 2019-12-31 | ₩3802.85 | ₩43700.00 | x |
| 2020-12-31 | ₩4310.30 | ₩43700.00 | x |
| 2021-12-31 | ₩20932.18 | ₩43700.00 | x |
| 2022-12-31 | ₩22683.12 | ₩43700.00 | x |
| 2023-12-31 | ₩22177.60 | ₩43700.00 | x |
| 2024-12-31 | ₩23462.42 | ₩43700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SK Bioscience Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.14%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.58x
- Recent ROE (-2.99%) is below the historical average (6.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.20% | 0.48% | 0.22x | 1.91x | ₩-20.65 Billion |
| 2019 | 6.31% | 7.98% | 0.46x | 1.74x | ₩-8.60 Billion |
| 2020 | 12.47% | 14.58% | 0.40x | 2.13x | ₩6.51 Billion |
| 2021 | 22.18% | 38.23% | 0.44x | 1.32x | ₩195.01 Billion |
| 2022 | 7.03% | 26.81% | 0.21x | 1.23x | ₩-51.72 Billion |
| 2023 | 1.31% | 6.04% | 0.20x | 1.09x | ₩-148.07 Billion |
| 2024 | -2.99% | -20.14% | 0.09x | 1.58x | ₩-234.14 Billion |
Industry Comparison
This section compares SK Bioscience Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SK Bioscience Co Ltd (302440) | ₩2.07 Trillion | 0.20% | 0.41x | $773.24 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |